Grace Therapeutics, Inc GRCE

Healthcare

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc

Bullboard Posts

Comment by Rosmorducon Apr 01, 2020 3:07pm

115 Views

Post# 30869480

RE:RE:About time

Francine,

on the flip side, they are confident with what will happen in June or else they wouldn't doing this now.

We may very well see the stock pop up 5 fold as soon as the Trilogy 2 results are opened after the FDA meeting ang go-forward plan.

There is always good and bad in everything.

I don't think much of Jan either but CAPRE is a winner for me and eventually this company will be taken out by big pharma once the NDA is in place and we can all be happy.

What do you think?

Bullboard Posts

Changing Europe’s dependency on HREE from China